The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $328.83, a 15.51% upside from current levels. In a report released yesterday, Citi also maintained a Hold ...

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Analyst Phipps says Amgen shares are up 15% year-to-date, although it remains volatile as investors debate clinical updates with MariTide given the significant market opportunity and competitive ...

Update on AMGN’s Diabetes/Obesity Pipeline Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing.

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of $5.26 per share. Earnings rose 21% year over year as higher revenues were ...

Explore Amgen's Q2 2025 earnings insights, showcasing 9% revenue growth, robust product performance, and innovation in obesity, rare disease, and ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US ...